Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
42
CCAP Quote, Financials, Valuation and Earnings
Last price:
$14.65
Seasonality move
:
-2.23%
Day range:
$14.47 - $14.71
52-week range:
$13.54 - $20.19
Dividend yield:
12.56%
P/E ratio:
10.93x
P/S ratio:
8.97x
P/B ratio:
0.75x
Volume:
194.2K
Avg. volume:
306.8K
1-year change:
-23.9%
Market cap:
$543M
Revenue:
$83.5M
EPS (TTM):
$1.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CCAP
Crescent Capital BDC
|
$42.5M | $0.47 | 85.64% | -14.91% | $17.33 |
|
DMYY
dMY Squared Technology Group
|
-- | -- | -- | -- | -- |
|
FHLT
Future Health ESG
|
-- | -- | -- | -- | -- |
|
GMFI
Aetherium Acquisition
|
-- | -- | -- | -- | -- |
|
GRAF
Graf Global
|
-- | -- | -- | -- | -- |
|
LEGT
Legato Merger Corp III
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CCAP
Crescent Capital BDC
|
$14.65 | $17.33 | $543M | 10.93x | $0.42 | 12.56% | 8.97x |
|
DMYY
dMY Squared Technology Group
|
$12.56 | -- | $49.2M | 59.33x | $0.00 | 0% | -- |
|
FHLT
Future Health ESG
|
$10.96 | -- | $65.1M | -- | $0.00 | 0% | -- |
|
GMFI
Aetherium Acquisition
|
$11.04 | -- | $56.4M | 367.67x | $0.00 | 0% | -- |
|
GRAF
Graf Global
|
$10.47 | -- | $301M | 39.46x | $0.00 | 0% | -- |
|
LEGT
Legato Merger Corp III
|
$10.72 | -- | $276.6M | 29.78x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CCAP
Crescent Capital BDC
|
55.39% | 0.392 | 142.31% | 0.62x |
|
DMYY
dMY Squared Technology Group
|
-- | -0.068 | -- | -- |
|
FHLT
Future Health ESG
|
-- | 0.000 | -- | -- |
|
GMFI
Aetherium Acquisition
|
-- | 0.000 | -- | -- |
|
GRAF
Graf Global
|
-- | 0.000 | -- | -- |
|
LEGT
Legato Merger Corp III
|
-- | -0.025 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CCAP
Crescent Capital BDC
|
-- | -- | 3.07% | 6.66% | 254.33% | -$15.1M |
|
DMYY
dMY Squared Technology Group
|
-- | -$492.2K | -- | -- | -- | -$773.6K |
|
FHLT
Future Health ESG
|
-- | -- | -- | -- | -- | -- |
|
GMFI
Aetherium Acquisition
|
-- | -$120.3K | -- | -- | -- | -$480.1K |
|
GRAF
Graf Global
|
-- | -$273.2K | -- | -- | -- | -$119.5K |
|
LEGT
Legato Merger Corp III
|
-- | -$167.1K | -- | -- | -- | -$86.2K |
Crescent Capital BDC vs. Competitors
-
Which has Higher Returns CCAP or DMYY?
dMY Squared Technology Group has a net margin of 54.76% compared to Crescent Capital BDC's net margin of --. Crescent Capital BDC's return on equity of 6.66% beat dMY Squared Technology Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CCAPCrescent Capital BDC-- $0.11 $1.6B DMYYdMY Squared Technology Group-- -$1.16 -- -
What do Analysts Say About CCAP or DMYY?
Crescent Capital BDC has a consensus price target of $17.33, signalling upside risk potential of 18.32%. On the other hand dMY Squared Technology Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Crescent Capital BDC has higher upside potential than dMY Squared Technology Group, analysts believe Crescent Capital BDC is more attractive than dMY Squared Technology Group.
Company Buy Ratings Hold Ratings Sell Ratings CCAPCrescent Capital BDC3 2 0 DMYYdMY Squared Technology Group0 0 0 -
Is CCAP or DMYY More Risky?
Crescent Capital BDC has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison dMY Squared Technology Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CCAP or DMYY?
Crescent Capital BDC has a quarterly dividend of $0.42 per share corresponding to a yield of 12.56%. dMY Squared Technology Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crescent Capital BDC pays 102.15% of its earnings as a dividend. dMY Squared Technology Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCAP or DMYY?
Crescent Capital BDC quarterly revenues are $7.1M, which are larger than dMY Squared Technology Group quarterly revenues of --. Crescent Capital BDC's net income of $3.9M is higher than dMY Squared Technology Group's net income of -$4.6M. Notably, Crescent Capital BDC's price-to-earnings ratio is 10.93x while dMY Squared Technology Group's PE ratio is 59.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crescent Capital BDC is 8.97x versus -- for dMY Squared Technology Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCAPCrescent Capital BDC8.97x 10.93x $7.1M $3.9M DMYYdMY Squared Technology Group-- 59.33x -- -$4.6M
-
Which has Higher Returns CCAP or FHLT?
Future Health ESG has a net margin of 54.76% compared to Crescent Capital BDC's net margin of --. Crescent Capital BDC's return on equity of 6.66% beat Future Health ESG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CCAPCrescent Capital BDC-- $0.11 $1.6B FHLTFuture Health ESG-- -- -- -
What do Analysts Say About CCAP or FHLT?
Crescent Capital BDC has a consensus price target of $17.33, signalling upside risk potential of 18.32%. On the other hand Future Health ESG has an analysts' consensus of -- which suggests that it could fall by --. Given that Crescent Capital BDC has higher upside potential than Future Health ESG, analysts believe Crescent Capital BDC is more attractive than Future Health ESG.
Company Buy Ratings Hold Ratings Sell Ratings CCAPCrescent Capital BDC3 2 0 FHLTFuture Health ESG0 0 0 -
Is CCAP or FHLT More Risky?
Crescent Capital BDC has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison Future Health ESG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CCAP or FHLT?
Crescent Capital BDC has a quarterly dividend of $0.42 per share corresponding to a yield of 12.56%. Future Health ESG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crescent Capital BDC pays 102.15% of its earnings as a dividend. Future Health ESG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCAP or FHLT?
Crescent Capital BDC quarterly revenues are $7.1M, which are larger than Future Health ESG quarterly revenues of --. Crescent Capital BDC's net income of $3.9M is higher than Future Health ESG's net income of --. Notably, Crescent Capital BDC's price-to-earnings ratio is 10.93x while Future Health ESG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crescent Capital BDC is 8.97x versus -- for Future Health ESG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCAPCrescent Capital BDC8.97x 10.93x $7.1M $3.9M FHLTFuture Health ESG-- -- -- --
-
Which has Higher Returns CCAP or GMFI?
Aetherium Acquisition has a net margin of 54.76% compared to Crescent Capital BDC's net margin of --. Crescent Capital BDC's return on equity of 6.66% beat Aetherium Acquisition's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CCAPCrescent Capital BDC-- $0.11 $1.6B GMFIAetherium Acquisition-- $0.02 -- -
What do Analysts Say About CCAP or GMFI?
Crescent Capital BDC has a consensus price target of $17.33, signalling upside risk potential of 18.32%. On the other hand Aetherium Acquisition has an analysts' consensus of -- which suggests that it could fall by --. Given that Crescent Capital BDC has higher upside potential than Aetherium Acquisition, analysts believe Crescent Capital BDC is more attractive than Aetherium Acquisition.
Company Buy Ratings Hold Ratings Sell Ratings CCAPCrescent Capital BDC3 2 0 GMFIAetherium Acquisition0 0 0 -
Is CCAP or GMFI More Risky?
Crescent Capital BDC has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison Aetherium Acquisition has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CCAP or GMFI?
Crescent Capital BDC has a quarterly dividend of $0.42 per share corresponding to a yield of 12.56%. Aetherium Acquisition offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crescent Capital BDC pays 102.15% of its earnings as a dividend. Aetherium Acquisition pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCAP or GMFI?
Crescent Capital BDC quarterly revenues are $7.1M, which are larger than Aetherium Acquisition quarterly revenues of --. Crescent Capital BDC's net income of $3.9M is higher than Aetherium Acquisition's net income of $106.3K. Notably, Crescent Capital BDC's price-to-earnings ratio is 10.93x while Aetherium Acquisition's PE ratio is 367.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crescent Capital BDC is 8.97x versus -- for Aetherium Acquisition. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCAPCrescent Capital BDC8.97x 10.93x $7.1M $3.9M GMFIAetherium Acquisition-- 367.67x -- $106.3K
-
Which has Higher Returns CCAP or GRAF?
Graf Global has a net margin of 54.76% compared to Crescent Capital BDC's net margin of --. Crescent Capital BDC's return on equity of 6.66% beat Graf Global's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CCAPCrescent Capital BDC-- $0.11 $1.6B GRAFGraf Global-- $0.08 -- -
What do Analysts Say About CCAP or GRAF?
Crescent Capital BDC has a consensus price target of $17.33, signalling upside risk potential of 18.32%. On the other hand Graf Global has an analysts' consensus of -- which suggests that it could fall by --. Given that Crescent Capital BDC has higher upside potential than Graf Global, analysts believe Crescent Capital BDC is more attractive than Graf Global.
Company Buy Ratings Hold Ratings Sell Ratings CCAPCrescent Capital BDC3 2 0 GRAFGraf Global0 0 0 -
Is CCAP or GRAF More Risky?
Crescent Capital BDC has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison Graf Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CCAP or GRAF?
Crescent Capital BDC has a quarterly dividend of $0.42 per share corresponding to a yield of 12.56%. Graf Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crescent Capital BDC pays 102.15% of its earnings as a dividend. Graf Global pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCAP or GRAF?
Crescent Capital BDC quarterly revenues are $7.1M, which are larger than Graf Global quarterly revenues of --. Crescent Capital BDC's net income of $3.9M is higher than Graf Global's net income of $2.2M. Notably, Crescent Capital BDC's price-to-earnings ratio is 10.93x while Graf Global's PE ratio is 39.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crescent Capital BDC is 8.97x versus -- for Graf Global. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCAPCrescent Capital BDC8.97x 10.93x $7.1M $3.9M GRAFGraf Global-- 39.46x -- $2.2M
-
Which has Higher Returns CCAP or LEGT?
Legato Merger Corp III has a net margin of 54.76% compared to Crescent Capital BDC's net margin of --. Crescent Capital BDC's return on equity of 6.66% beat Legato Merger Corp III's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CCAPCrescent Capital BDC-- $0.11 $1.6B LEGTLegato Merger Corp III-- $0.08 -- -
What do Analysts Say About CCAP or LEGT?
Crescent Capital BDC has a consensus price target of $17.33, signalling upside risk potential of 18.32%. On the other hand Legato Merger Corp III has an analysts' consensus of -- which suggests that it could fall by --. Given that Crescent Capital BDC has higher upside potential than Legato Merger Corp III, analysts believe Crescent Capital BDC is more attractive than Legato Merger Corp III.
Company Buy Ratings Hold Ratings Sell Ratings CCAPCrescent Capital BDC3 2 0 LEGTLegato Merger Corp III0 0 0 -
Is CCAP or LEGT More Risky?
Crescent Capital BDC has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison Legato Merger Corp III has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CCAP or LEGT?
Crescent Capital BDC has a quarterly dividend of $0.42 per share corresponding to a yield of 12.56%. Legato Merger Corp III offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crescent Capital BDC pays 102.15% of its earnings as a dividend. Legato Merger Corp III pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCAP or LEGT?
Crescent Capital BDC quarterly revenues are $7.1M, which are larger than Legato Merger Corp III quarterly revenues of --. Crescent Capital BDC's net income of $3.9M is higher than Legato Merger Corp III's net income of $2.1M. Notably, Crescent Capital BDC's price-to-earnings ratio is 10.93x while Legato Merger Corp III's PE ratio is 29.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crescent Capital BDC is 8.97x versus -- for Legato Merger Corp III. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCAPCrescent Capital BDC8.97x 10.93x $7.1M $3.9M LEGTLegato Merger Corp III-- 29.78x -- $2.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
